Seres Therapeutics, Inc. (MCRB) is a Biotechnology company in the Healthcare sector, currently trading at $8.61. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of MCRB = $6.87 (-20.2% from the current price, the stock appears overvalued). Analyst consensus target is MCRB = $1 (-85.5% upside).
Valuation: MCRB trades at a trailing Price-to-Earnings (P/E) of 13.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.17.
Financials: revenue is $789,000, +786.1%/yr average growth. Net income is $6M, growing at +1414.5%/yr. Net profit margin is 721.9% (strong). Gross margin is -423.8% (-509.7 pp trend).
Balance sheet: total debt is $83M against $44M equity (Debt-to-Equity (D/E) ratio 1.88, leveraged). Current ratio is 2.56 (strong liquidity). Debt-to-assets is 60%. Total assets: $138M.
Analyst outlook: 11 / 18 analysts rate MCRB as buy (61%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 54/100 (Partial), Growth 100/100 (Pass), Past 50/100 (Partial), Health 50/100 (Partial), Moat 0/100 (Fail), Future 37/100 (Fail), Income 100/100 (Pass).
